
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Editorial
Jon S. Berlin, MD
View From the ED
Leslie S. Zun, MD, MBA
Clinical Case Presentations
Leslie S. Zun, MD, MBA
Commentary
Avrim B. Fishkind, MD
also inside: Reader Forum, Literature Highlights




